Huasheng Biological receives 3.4374 million yuan in government subsidies

Radar Finance | Written by Yang Yang | Edited by Li Yihui

On February 24, Wuhan Huisheng Biotechnology Co., Ltd. (Stock abbreviation: Huisheng Biotech, Stock code: 300871) announced that the company recently received government subsidy funds totaling 3.4374 million yuan, accounting for 17.05% of the company’s latest audited net profit attributable to shareholders of the listed company. The subsidies were received on February 10, 2026, and February 12, 2026, in amounts of 500,000 yuan and 2.9374 million yuan respectively. The subsidies are in cash, related to the company’s daily operations, and are not sustainable.

According to the relevant provisions of “Enterprise Accounting Standard No. 16—Government Grants,” the government subsidies received this time are related to income and are expected to increase the total profit for 2026 by 3.4374 million yuan. The subsidy data are unaudited, and the final accounting treatment and impact on the company’s 2026 financial results will be subject to the audit results of the annual auditing firm.

Tianyancha data shows that Huisheng Biotech was established on January 25, 2002, with a registered capital of 202.332557 million yuan. The legal representative is Zhang Weiyuan. The registered address is No. 52 Yousha Road, Xinjiao Street Office, Dongxihu District, Wuhan, Hubei Province. Its main business includes the research, production, and sales of veterinary drugs (including chemical preparations, raw materials, and traditional Chinese medicine preparations), feed, and additives.

Currently, the company’s chairman is Zhang Weiyuan, the secretary of the board is Wang Qingfeng, with 1,028 employees. The actual controllers are Zhang Weiyuan and Yu Jiao’e.

The company has 9 associated companies, including Hubei Province Animal Health Technology Development Co., Ltd., Wuhan Musheng Biotechnology Co., Ltd., Hubei Hesheng Biopharmaceutical Co., Ltd., Miracle Pharm Pte. Ltd., Viet Thanh Bio Technology Company Limited, among others.

In terms of performance, the company’s operating income for 2022, 2023, and 2024 was 1.023 billion yuan, 1.02 billion yuan, and 1.2 billion yuan, respectively, with year-on-year growth of 2.68%, -0.31%, and 17.71%. The net profit attributable to shareholders was 52.7065 million yuan, 16.7808 million yuan, and -20.1556 million yuan, with year-on-year changes of -60.33%, -68.16%, and -220.11%. During the same period, the company’s asset-liability ratio was 48.43%, 49.28%, and 51.40%.

Regarding risks, Tianyancha information shows that the company has 408 internal Tianyan risks, 888 surrounding risks, 18 historical risks, and 225 warning risks.